Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › JUBLPHARMA

JUBLPHARMA

Jubilant Pharmova Limited
Small-capPharma ↗

What the six lenses say about JUBLPHARMA — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹969.2
2026-07-10
VWAP · 1Y anchor
₹1048
-7.5% from VWAP
P/E · TTM
38.7×
TTM EPS ₹25.0
52-week range
38%
position low→high
RSI(14)
49
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How JUBLPHARMA’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
5.5
avg conviction decile
Leadership
0/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD550›

The actual numbers

Price vs VWAP (1y)-7.5%
EMA trend stackMixed
Price vs 200-EMA-1.1%
Price vs 50-EMA+0.4%
RSI(14)49
RS vs Nifty 500 · 3M+5.5%
RS vs sector · 3M-7.0%
52-week range38%
Volume vs 30d avg1.21×
Volume vs 60d avg0.98×
ATR(14) · volatility26.7
Bollinger width · vol contraction0.038
FundamentalD226›

The actual numbers

Return on equity (ROE)6.5%
Return on capital (ROCE)9.0%
Operating margin10.0%
Net margin4.8%
Revenue growth · YoY+14.4%
EPS growth · YoY-52.7%
Debt / equity0.51×

Full 8-quarter history in the financials table below.

ValuationD637›

The actual numbers

P/E (TTM)38.7×
TTM EPS₹25.0
52-week range38%
CatalystD332›

The actual numbers

Earnings & momentum26
Capital actions17
Governance82

Every filing in the corporate-announcements panel below.

FlowD650›

The actual numbers

Promoter holding47.7%
Delivery · 30d avg48.1%
Up/down-day asymmetry-0.7pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D5 + D6 ) ÷ 2 = 5.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Medium
50
Conviction score 50/100 · avg-decile strength 5.5/10
Conviction score50/100›
TechnicalD5›
FundamentalD2›
ValuationD6›
CatalystD3›
FlowD6›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-0.5pp
+0.5pp
-2.7pp
+9.2pp
-2.2pp
-11.8pp
Nifty 500
Broad-market baseline
-0.9pp
+0.4pp
-3.3pp
+5.5pp
-7.3pp
-15.6pp
Sector
Own-sector index
—
—
-5.7pp
-7.0pp
-21.6pp
-33.5pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

JUBLPHARMA daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
969.20-1.55

Relative strength

RS vs baseline · rebased to 100

JUBLPHARMA ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
132.92-1.22

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)1,7321,7521,8221,9291,9011,9662,1222,290
↳ change QoQ—+1.2%+4.0%+5.9%-1.5%+3.4%+7.9%+7.9%
EBITDA (₹cr)661297278345290341289339
EBITDA margin38.2%16.9%15.2%17.9%15.3%17.3%13.6%14.8%
PAT (₹cr)48210310115110212056119
↳ change QoQ—-78.7%-1.8%+50.0%-32.5%+17.6%-53.3%+112.5%
Net margin27.8%5.9%5.5%7.8%5.4%6.1%2.6%5.2%
EPS (₹)30.446.476.379.646.467.553.517.50
D/E————————
YoY growth · Mar '26Revenue +18.7% YoYPAT -21.2% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 19 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    LOWgovernance
    Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    MEDIUMgovernance
    Resignation of Director/KMP/SMP
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    MEDIUMgovernance
    Resignation
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 22 May '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 22 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 22 May '26
    MEDIUMcapital
    Dividend
    ›

    A dividend declaration — a cash return to shareholders.

    View original filing on NSE ↗
  • 22 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds JUBLPHARMA

Mutual funds holding JUBLPHARMA (10)

FundWeightAUM ₹crGrade
Quant Small Cap Gr0.92%31,774
Bandhan Small Cap Reg Gr1.31%27,219
Kotak Multicap Reg Gr0.71%26,249
Aditya BSL Small Cap Gr0.91%5,453
HDFC Pharma and Healthcare Reg Gr1.34%2,362
Kotak Consumption Reg Gr1.68%1,668
Tata India Pharma & Healthcare Reg Gr0.55%1,387
UTI Healthcare Reg Gr0.73%1,217
Abakkus Small Cap Reg Gr1.42%1,089
Aditya BSL Pharma & Hlthcare Reg Gr0.66%950

ETFs holding JUBLPHARMA (2)

ETFWeightGrade
Mirae Asset Nifty 500 Healthcare ETF0.63%
Motilal Oswal BSE Healthcare ETF0.54%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma